Managed Care Considerations for a First-in-Class M1/M4 Muscarinic Agonist for the Treatment of Adults With Schizophrenia
Advertisement
Advertisement
Trending on AJMC
1
Promises and Pitfalls of AI in Health Care
2
Texas Sues J&J, Kenvue for Alleged Deception in Acetaminophen Marketing
3
Paul Ryan Champions Health Care Policy Reform, AI Amid Government Shutdown
4
Persistent Barriers Keep Oral HIV PrEP Out of Reach for High-Risk Groups
5
